Tafenoquine for preventing relapse in people with Plasmodium vivax malaria

  title={Tafenoquine for preventing relapse in people with Plasmodium vivax malaria},
  author={Senaka Rajapakse and Chaturaka Rodrigo and Sumadhya Deepika Fernando},
  booktitle={The Cochrane database of systematic reviews},
BACKGROUND Plasmodium vivax malaria is widespread, and the persistent liver stage causes relapse of the disease which contributes to continued P. vivax transmission. Primaquine is currently the only drug that cures the parasite liver stage, but requires 14 days to be effective and can cause haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. In addition, there is some evidence of parasite resistance to the drug. Tafenoquine is a new alternative with a longer half-life… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 11 extracted citations

Effects of Antimalarial Tafenoquine on Blood Platelet Activity and Survival.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology • 2017


Publications referenced by this paper.
Showing 1-4 of 4 references

Tafenoquine for Plasmodium vivax malaria infection

S Rajapakse 2013 Rajapakse, C Rodrigo, SD. Fernando
Cochrane Database of Systematic Reviews • 2013

Primaquine therapy for malaria.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2004

Similar Papers

Loading similar papers…